Rising Rates of Teenage E-cigarette Use in the US

Oct.20.2022
Rising Rates of Teenage E-cigarette Use in the US
Teenage e-cigarette use rises in the US, with 14.1% of high school students and 3.3% of middle school students using them. Experts warn of health risks.

The proportion of teenagers using e-cigarettes has increased once again, according to a report released by the US Centers for Disease Control and Prevention. The National Youth Tobacco Survey, led by the US Food and Drug Administration and the CDC, showed that 14.1% of high school students and 3.3% of middle school students reported using e-cigarettes or other vaping products in the recent past. These figures suggest that approximately 2.5 million middle and high school students in the US are now vaping. Experts are particularly concerned that over a quarter of students are using e-cigarettes on a daily basis.


Dr. Ramiro Fernandez, Assistant Professor at the Division of Thoracic Surgery under Dr. David J. Sugarbaker at the Michael E. DeBakey College of Medicine, states that while extensive long-term data on the effects of electronic cigarettes are lacking, we are aware of acute lung injuries associated with their use, known as EVALI or electronic cigarette-associated lung injury.


Patients with EVALI experience respiratory symptoms and signs, including shortness of breath and decreased oxygen levels. They may also develop severe diffuse inflammation in their lungs, which can lead to death," said Fernandez. As of February 2020, there have been 2,807 reported cases of hospitalization or death due to EVALI, with 68 confirmed deaths.


Most e-cigarettes contain nicotine. In fact, a study by the Centers for Disease Control and Prevention found that 99% of e-cigarettes sold in assessment locations in the US contained nicotine. Nicotine can harm the developing brains of adolescents, which do not fully mature until around age 25. Additionally, research shows that teenagers who use e-cigarettes are more likely to start smoking traditional cigarettes in the future.


Electronic cigarettes also contain other harmful substances, such as ultrafine particles that can be inhaled deep into the lungs, flavorings associated with serious lung diseases, heavy metals like nickel, tin, and lead, as well as other carcinogens.


According to the American Cancer Society, the aerosol in e-cigarettes contains addictive substances that can lead to lung disease, heart disease, and cancer. A study by Johns Hopkins University in October 2021 on the components of e-cigarettes shows that there are thousands of chemical components in e-cigarette products, many of which have not been identified. The research team identified a pesticide, three chemicals never before found in e-cigarettes, and two flavorings associated with respiratory irritation and potential toxicity.


Although some people believe that electronic cigarettes can help people quit smoking, they have not been approved by the Food and Drug Administration as an aid. To quit smoking, seek help from your doctor or other support services, such as the smoking cessation program at the Baylor College of Medicine's Chest Clinic. It is important to note that electronic cigarettes are harmful not only to young people but also to adults.


People need to know that electronic cigarettes are harmful to your health," Dr. Fernandez stated. "Although the long-term effects are still unclear, data shows noticeable risks to cardiovascular and lung health.


For more information and resources, please see Baylor College of Medicine's position paper on taking action to address the issue of youth smoking and vaping.


Author: Tiffany Harston, Assistant to the Michael E. DeBakey Surgical Communications at Baylor College of Medicine.


Statement:


This article is compiled from third-party information and is intended for industry professionals for informational and educational purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for internal industry exchange and research purposes.


Due to the limitations of the compiler's skills, the translated article may not express the same meaning as the original. Please refer to the original article for accuracy.


In regards to any domestic, Hong Kong/Macau/Taiwan-related, or foreign statements and positions, 2FIRSTS is fully aligned with the Chinese government.


The copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australian Coalition Unveils Illicit Tobacco Plan With 80% Excise Cut and Legal, Taxed Vapes and Nicotine Pouches
Australia’s Coalition has unveiled a national illicit-tobacco policy that would cut tobacco excise by 80% and create legal, regulated and taxed adult markets for vaping products and nicotine pouches if it wins government. The plan proposes an excise of A$0.50 per millilitre of e-liquid and A$0.025 per milligram of nicotine in pouches, alongside A$200 million in additional enforcement and a A$60 million three-year public-awareness campaign. The Coalition says the package would narrow the price advantage of illicit products and undermine organised crime, while Labor and public-health groups warn that dramatically cheaper cigarettes could reverse long-term declines in smoking.
Sep.03
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives